资讯

Abbvie raises 2025 EPS guidance to $12.09-$12.29 amid strong Skyrizi and Rinvoq growth
AbbVie Inc. reports a strong Q1 2025 with EPS of $2.46 and raised guidance, fueled by Skyrizi, Rinvoq, and neuroscience growth.